To study pancreatic, breast and small-cell lung cancers, Sunshine Biopharma Inc., of Montreal, has initiated studies of Adva-27a, designed to shrink tumors, in xenograft mice with tumors. Adva-27a is a GEM-difluorinated C-glycoside derivative of podophyllotoxin and is designed to inhibit the enzyme topoisomerase II.
Petagene Ltd., of Cambridge, U.K., said its Petasuite software has been selected to compress the genomics datasets for Cambridge, U.K.-based Astrazeneca plc's Centre for Genomics Research (CGR). To date, the center has processed more than 200,000 genomics datasets, generating over a petabyte of data. The compression software will enable the CGR to compress more than 200,000 BAM files in a 24-hour period and will add the compressed data to tiered cloud storage.
Botanix Pharmaceuticals Ltd., of Sydney, said it was awarded an AU$50,000 (US$33,788) Innovation Connections Grant from the Australian government to accelerate its medicinal chemistry program targeting the creation of synthetic analogues of cannabidiol and the investigation of cannabidiol's antimicrobial activity.
Femtogenix Ltd., of Harpenden, U.K., which is developing the next generation of DNA-interactive antibody drug conjugate (ADC) payloads, said data verifying the favorable toxicity profile and potent efficacy of its pyridinobenzodiazepine (PDD) ADC payload platform in tumor cell models were presented at the World ADC 2019 meeting in San Diego.
Pfenex Inc., of San Diego, said its partner, Alvogen Inc., entered exclusive commercialization agreements for PF-708 to treat osteoporosis in patients at high risk of fracture with Pharmbio Korea, Jamp Pharma in Canada and Kamada Ltd. in Israel. Under the agreement, Pfenex is eligible to receive milestone payments and a percentage of net sales or transfer price.
Theratechnologies Inc., of Montreal, said its shares began trading on Nasdaq under the symbol TXTX on Thursday. Shares will continue to be listed on the Toronto Stock Exchange under the symbol TH.
Galderma Pharma SA, of Lausanne, Switzerland, received a manufacturing license from the Swedish Medical Products Agency for a facility in Uppsala, Sweden. The facility will manufacture Galderma's QM-1114, a botulinum toxin derived from a strain of Clostridium botulinum.
RSS